Janssen Research & Development,
LLC (Janssen) today announced the launch of EXPLORER, a comprehensive, global
research program for XARELTO^® (rivaroxaban), an oral anticoagulant. The
program includes studies that will evaluate XARELTO^® for investigational use
in patients with chronic heart failure and in those with coronary artery
disease or peripheral artery disease.
XARELTO^® does not require routine blood monitoring, and with approvals for
six distinct uses, it has the broadest indication profile of any of the newer
oral anticoagulants in the market today. XARELTO^® is approved in the U.S. for
reducing the risk of strokes in patients with nonvalvular atrial fibrillation;
as a treatment for deep vein thrombosis and pulmonary embolism and to prevent
recurrence of these events; and for reducing the risk of blood clots in the
legs and lungs of people who have had hip or knee replacement surgery.
The extensive program of clinical trials evaluating XARELTO^® makes the
compound the most studied oral, Factor Xa inhibitor in the world today. By the
time of its completion, more than 100,000 patients will have participated in
the XARELTO^® clinical development program.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in